MMI Advances REMIND Alzheimer’s Study After FDA IDE Approval
JACKSONVILLE, Fla., July 30, 2026 Medical Microinstruments (MMI) announced that the U.S. Food and Drug Administration (FDA) has approved...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
JACKSONVILLE, Fla., July 30, 2026 Medical Microinstruments (MMI) announced that the U.S. Food and Drug Administration (FDA) has approved...
JACKSONVILLE, FL, May 04, 2026 Medical Microinstruments (MMI) has successfully treated the first patient in its FDA-approved REMIND clinical...
